26 Jul Xintela
Evy Lundgren-Åkerlund, CEO
Oct. 10 | 5:30pm | Ecolab Life Sciences Ballroom
Lund, Sweden
(STO: XINT)
Xintela is a clinical-stage biopharma company developing allogeneic MSC-based therapies. Xintela’s proprietary product platform XSTEM® consists of homogenous integrin α10β1-selected adipose tissue derived MSCs with superior potency and consistency. XSTEM is manufactured in Xintela’s own GMP facility. In a First-in-Human study (Phase I/IIa) on knee osteoarthritis (OA) patients (KL grade II-III), 24 patients have been dosed with three different dose levels of XSTEM. Safety and preliminary efficacy are assessed every 6 month up to 18 months. XSTEM has also entered into a Phase I/IIa clinical study for the treatment of difficult-to-heal venous leg ulcers (VLU). Preclinical studies in large animals, support disease modifying effects in OA and VLU and also for the treatment of Acute Respiratory Distress Syndrome (ARDS). During 2023 we expect safety from all dose levels and early efficacy signals from the OA study as well as safety and early efficacy signals from the VLU study.
